Quarterly report pursuant to Section 13 or 15(d)

Debt (Tables)

v3.10.0.1
Debt (Tables)
3 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
Interest Rate Contracts
The following table presents information related to interest rate contracts entered into by the Company and designated as cash flow hedges:
 
 
December 31, 2018
 
September 30, 2018
Pay fixed swaps - notional amount
 
$
337,500

 
$
343,750

Net unrealized gain 
 
$
7,467

 
$
11,309

Weighted-average maturity period (years)
 
2.5

 
2.7

Weighted-average received rate
 
2.50
%
 
2.26
%
Weighted-average pay rate
 
1.38
%
 
1.37
%
Interest Rate Swap Contracts as Reflected on Balance Sheet
At December 31, 2018 and September 30, 2018, the interest rate swap contracts were reflected in the Consolidated Balance Sheets as follows:
Derivatives
 
December 31, 2018
 
September 30, 2018
Current assets:
 
 
 
 
Other current assets
 
$
2,853

 
$
3,867

Long-term assets:
 
 

 
 

Other assets
 
4,614

 
7,442

Current liabilities:
 
 

 
 

Other current liabilities
 

 

Long-term liabilities:
 
 

 
 

Other liabilities
 

 

Total derivatives
 
$
7,467

 
$
11,309

Gain (Loss) on Derivatives
The gains recognized on derivatives were as follows:
 
Derivatives in Cash Flow Hedging Relationships
 
Location of Gain Recognized in Income on Derivative
 
Amount of Gain Recognized in Income on Derivatives
 
 
 
 
 
  
 
Three Months Ended
December 31,
 
 
 
 
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Interest rate swaps
 
Interest expense
 
$
735

 
$
63



Note 6.   Debt (continued)

The Company recognized the following (losses) gains in AOCI:
Derivatives in Cash Flow Hedging Relationships
 
Amount of (Loss) Gain
Recognized in AOCI on Derivatives
 
Location of Gain Reclassified From AOCI into Income (Effective Portion*)
 
Amount of Gain 
Reclassified from
AOCI into Income
(Effective Portion*)
 
 
December 31, 2018
 
December 31, 2017
 
 
 
December 31, 2018
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Interest rate swaps
 
$
(2,346
)
 
$
1,633

 
Interest expense
 
$
555

 
$
38

 
 
 
 
 
 
 
 
 
 
 
*There is no ineffective portion or amount excluded from effectiveness testing.